Prospects of personalized medicine in cardiovascular diseases

Metabolism: Clinical and Experimental

Volumn 62, Issue SUPPL.1, 2013, Pages

  Lenfant, Claude ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL AORTA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; FOOD AND DRUG ADMINISTRATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEREDITY; HUMAN; HYPERTENSION; INTRACRANIAL ANEURYSM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

EID: 84870542272     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.08.018     Document Type: Article

References (45)

1. World Health Organization: the global burden of disease: 2004 update. 2008.
2. W.C. Willett Balancing life-style and genomics research for disease prevention Science 296 2002 695 698
3. A. Helgadottir, G. Thorleifsson, and A. Manolescu A common variant on chromosome 9p21 affects the risk of myocardial infarction Science 316 2007 1491 1493
4. A. Helgadottir, G. Thorleifsson, and K.P. Magnusson The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm Nat Genet 40 2008 217 224
5. C. Cluett, M.M. McDermott, and J. Guralnik The 9p21 myocardial infarction risk allele increases risk of peripheral artery disease in older people Circ Cardiovasc Genet 2 2009 347 353
6. R. McPherson, A. Pertsemlidis, and N. Kavaslar A common allele on chromosome 9 associated with coronary heart disease Science 316 2007 1488 1491
7. N.J. Samani, O.T. Raitakari, and K. Sipila Coronary artery disease-associated locus on chromosome 9p21 and early markers of atherosclerosis Arterioscler Thromb Vasc Biol 28 2008 1679 1683
8. H. Schunkert, I.R. Konig, and S. Kathiresan Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease Nat Genet 43 2011 333 338
9. R.A. Wilke, R.U. Simpson, and B.N. Mukesh Genetic variation in CYP27B1 is associated with congestive heart failure in patients with hypertension Pharmacogenomics 10 2009 1789 1797
10. K. Ding, and I.J. Kullo Genome-wide association studies for atherosclerotic vascular disease and its risk factors Circ Cardiovasc Genet 2 2009 63 72
11. D. Altshuler, M.J. Daly, and E.S. Lander Genetic mapping in human disease Science 322 2008 881 888
12. T.A. Manolio, L.D. Brooks, and F.S. Collins A HapMap harvest of insights into the genetics of common disease J Clin Invest 118 2008 1590 1605
13. T.A. Manolio Genomewide association studies and assessment of the risk of disease N Engl J Med 363 2010 166 176
14. A.J. Marian, and J. Belmont Strategic approaches to unraveling genetic causes of cardiovascular diseases Circ Res 108 2011 1252 1269
15. E.E. Ntzani, G. Liberopoulos, and T.A. Manolio Consistency of genome-wide associations across major ancestral groups Hum Genet 2011 Dec 20 (Epub ahead of print)
16. C.J. O'Donnell, and E.G. Nabel Genomics of cardiovascular disease N Engl J Med 365 2011 2098 2109
17. D.M. Roden Personalized medicine and the genotype-phenotype dilemma J Interv Card Electrophysiol 31 2011 17 23
18. A.G. Motulsky Drug reactions enzymes, and biochemical genetics J Am Med Assoc 165 1957 835 837
19. J.A. Johnson, L.H. Cavallari, and A.L. Beitelshees Pharmacogenomics: application to the management of cardiovascular disease Clin Pharmacol Ther 90 2011 519 531
20. K. Musunuru Current role of pharmacogenomics in cardiovascular medicine Curr Treat Options Cardiovasc Med 13 2011 302 312
21. D.M. Roden, J.A. Johnson, and S.E. Kimmel Cardiovascular pharmacogenomics Circ Res 109 2011 807 820
22. E. Link, S. Parish, and J. Armitage SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 2008 789 799
23. D. Voora, S.H. Shah, and I. Spasojevic The SLCO1B1*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 2009 1609 1616
24. S.D. Maggo, M.A. Kennedy, and D.W. Clark Clinical implications of pharmacogenetic variation on the effects of statins Drug Saf 34 2011 1 19
25. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
26. B.J. Peters, A.M. Harmsze, and J.M. ten Berg CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel Pharmacogenomics 12 2011 141 144
27. E.M. Degoma, G. Rivera, and S.M. Lilly Personalized vascular medicine: individualizing drug therapy Vasc Med 16 2011 391 404
28. U. Amstutz, and B.C. Carleton Pharmacogenetic testing: time for clinical practice guidelines Clin Pharmacol Ther 89 2011 924 927
29. L. Wang, H.L. McLeod, and R.M. Weinshilboum Genomics and drug response N Engl J Med 364 2011 1144 1153
30. M.P. Turunen, E. Aavik, and S. Yla-Herttuala Epigenetics and atherosclerosis Biochim Biophys Acta 1790 2009 886 891
31. A. Baccarelli, R. Wright, and V. Bollati Ischemic heart disease and stroke in relation to blood DNA methylation Epidemiology 21 2010 819 828
32. B.G. Bruneau Epigenetic regulation of the cardiovascular system: introduction to a review series Circ Res 107 2010 324 326
33. J.M. Ordovas, and C.E. Smith Epigenetics and cardiovascular disease Nat Rev Cardiol 7 2010 510 519
34. A. Baccarelli, M. Rienstra, and E.J. Benjamin Cardiovascular epigenetics: basic concepts and results from animal and human studies Circ Cardiovasc Genet 3 2010 567 573
35. A.V. Shirodkar, and P.A. Marsden Epigenetics in cardiovascular disease Curr Opin Cardiol 26 2011 209 215
36. R.B. Schnabel, A. Baccarelli, and H. Lin Next steps in cardiovascular disease genomic research - sequencing, epigenetics, and transcriptomics Clin Chem 58 2012 113 126
37. A.E. Guttmacher, and F.S. Collins Genomic medicine - a primer N Engl J Med 347 2002 1512 1520
38. H. Varmus Getting ready for gene-based medicine N Engl J Med 347 2002 1526 1527
39. W.M. Gibson Can personalized medicine survive? Can Fam Physician 17 1971 29 33
40. W.G. Feero, A.E. Guttmacher, and F.S. Collins Genomic medicine - an updated primer N Engl J Med 362 2010 2001 2011
41. H. Varmus Ten years on - the human genome and medicine N Engl J Med 362 2010 2028 2029
42. Collins FS. Reengineering translational science: the time is right. Sci Transl Med 2011;3:90 cm17.
43. M.A. Hamburg, and F.S. Collins The path to personalized medicine N Engl J Med 363 2010 301 304
44. M.J. Khoury, M. Gwinn, and W. Burke Will genomics widen or help heal the schism between medicine and public health? Am J Prev Med 33 2007 310 317
45. M.J. Khoury, W.G. Feero, and M. Reyes The genomic applications in practice and prevention network Genet Med 11 2009 488 494